Australian immuno-oncology company Imugene (ASX:IMU) has relocated to accelerate development of its lead cancer therapy after reporting encouraging clinical results,…
Read More

Australian immuno-oncology company Imugene (ASX:IMU) has relocated to accelerate development of its lead cancer therapy after reporting encouraging clinical results,…
Read More
CEL-SCI Corporation, a biotechnology company focutilized on developing immunotherapies for cancer and other diseases, has released its 2025 10-K report.…
Read More